About Us
Delve deep into the field of metabolism and become a leader in the industry
Founded in September 2018, QL Biopharm specializes in the production of recombinant protein drugs using Escherichia coli. The company is committed to developing innovative biological drugs for the treatment of chronic metabolic diseases, such as diabetes, obesity, and nonalcoholic steatohepatitis, aiming to improve the quality of life for people around the world. Currently, there are 10 understudied recombinant protein innovative drugs and biosimilar varieties in QL Biopharm’s pipelines. By the end of 2022, two of our independently developed, world-leading innovative drugs and one domestic alternative international major variety generic drug had entered the clinical trial stage.